News & Events - Inventiva Pharma

News & Events

Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market

Inventiva annonce la mise à disposition d’un prospectus dans le cadre de son offre au public d’actions ordinaires sous la formes d’ADS à l’occasion de son introduction en bourse sur le Nasdaq Global Market (only in French)

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market

Inventiva announces the filing of an amended registration statement, including an estimated initial public offering price range

Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

H1 2020 Financial Information

Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

Load More

Upcoming Investors Meetings

Upcoming Science Conferences

Questions?
Get in touch!

Inventiva
Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com

News & Events